News

This designation is given to medications with the potential to treat rare conditions — those that affect fewer than 200,000 people in the U.S. Benefits include exemption from

“With the FDA’s expanded definition of Critical COVID-19 to include patients on all forms of ventilation and the recent trend at leading hospitals that avoids mechanical ventilators whenever

Eli Lilly’s partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralising antibody treatment, known as JS016, to treat Covid-19 disease. Junshi

The US-Dutch collaboration will focus on advancing 47D11, a fully human, neutralising antibody therapeutic candidate. Discovery of the antibody was reported last month by Utrecht University, Erasmus Medical

The clinical data were presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held as a virtual event on

The peer-reviewed case series of 19 hospitalised patients with COVID-19 disease and severe hypoxia and/or inflammation is a collaboration from investigators across the US, including AstraZeneca scientists, and

The regulator has approved a supplemental new drug application (sNDA) for Recarbrio to treat patients 18 years of age and older with HABP/VABP caused due to susceptible Gram-negative

According to Janssen, the subcutaneous formulation of daratumumab is administered as a fixed dose, which considerably brings down treatment time, from hours to nearly three to five minutes,

New institutional investors and family offices participated in the financing alongside original commitments from founding investors MPM Capital and F2 Ventures. Following the completion of the fundraising, Tim